Assessment Status |
NCPE assessment ongoing |
HTA ID |
22028 |
Drug |
Vosoritide |
Brand |
Voxzogo® |
Indication |
For the treatment of genetically confirmed achondroplasia in patients aged two years and older whose epiphyses are not closed. |
Rapid review commissioned |
09/05/2022 |
Rapid review completed |
01/06/2022 |
Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of vosoritide compared with the current standard of care. |
Full pharmacoeconomic assessment commissioned by HSE |
01/07/2022 |
Pre-submission consultation with Applicant |
26/09/2022 |
Full submission received from Applicant |
21/03/2023 |
Preliminary review sent to Applicant |
24/07/2023 |
NCPE assessment re-commenced |
22/08/2023 |
Factual accuracy sent to Applicant |
13/09/2023 |
NCPE assessment re-commenced |
22/09/2023 |